Claudia Giraldo
Research Subjects
Research Interests
Claudia Giraldo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amelia Granel
A. Granel, MD, San Roque de Gonnet Hospital
1 shared publication - Ana Ines Marcos
Hospital San Roque de Gonnet, La Plata, Argentina
1 shared publication - Emilce Edith Schneeberger
Rheumatology Section, Instituto de Rehabilitación Psicofísica (IREP), Ciudad Autonoma de Buenos Aires, Argentina
1 shared publication - Gustavo Citera
Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
1 shared publication - María de Los Angeles Correa
Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
1 shared publication - Oscar Rillo
Hospital. I. Pirovano, Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 19-22
Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
Objective: The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of patients with chronic inflammatory arthritis, we wonder whether it is necessary to monitor the MT infection after starting the biological treatment. To evaluate the frequency of the tuberculin skin test (TST) conversion and its association with an active TB infection and other disease variables. Methods: Patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and spondyloarthritis (SpA) receiving treatment with anti-TNF, tocilizumab, and/or abatacept agents were included into the study. Patients had to have a negative TST (
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 6 (1) , 19-22
Open AccessTuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
Objective: The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of patients with chronic inflammatory arthritis, we wonder whether it is necessary to monitor the MT infection after starting the biological treatment. To evaluate the frequency of the tuberculin skin test (TST) conversion and its association with an active TB infection and other disease variables. Methods: Patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and spondyloarthritis (SpA) receiving treatment with anti-TNF, tocilizumab, and/or abatacept agents were included into the study. Patients had to have a negative TST (